The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

RFK Jr. is declaring war on chronic illness, which, if he succeeds, will not only make us healthier but will also cut down ...

Anti-obesity drug Mounjaro is set to rack up global sales worth nearly £22bn a year by the end of the decade. But Donald ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Tori Allen says she's thrilled to have lost 80 pounds since she went on Wegovy, one of the GLP-1 drugs that more and more people are using to treat diabetes or lose weight.

In a ginormous new study, researchers have begun mapping the manifold health benefits of drugs like Ozempic and Wegovy beyond ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...